

L.N. 144 of 2015

Dangerous Drugs Ordinance (Amendment of First Schedule) Order 2015

(Made by the Chief Executive under section 50(1) of the Dangerous Drugs Ordinance (Cap. 134) after consultation with the Executive Council)

1. Commencement

This Order comes into operation on 27 November 2015.

2. Dangerous Drugs Ordinance amended

The Dangerous Drugs Ordinance (Cap. 134) is amended as set out in section 3.

3. First Schedule amended

- (1) First Schedule, Part I, paragraph 1(a), after item “Nabilone”—

Add

“Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone”.

- (2) First Schedule, Part I, paragraph 1(a), after item “Quinalbarbitone”—

Add

“Quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate

Quinolin-8-yl 1-fluoropentyl-1H-indole-3-carboxylate

Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate”.

- (3) First Schedule, Part I, paragraph 1(a), after item “Zipeprol”—

Add

“N-(Adamant-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide

N-(Adamant-1-yl)-1-pentyl-1H-indazole-3-carboxamide

N-(Adamant-1-yl)-1-pentyl-1H-indole-3-carboxamide

N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide

N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide

N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide

N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide”.

- (4) First Schedule, Part I, paragraph 1(a), after item “1-Benzylpiperazine”—

Add

“4-Bromo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine

4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine”.

- (5) First Schedule, Part I, paragraph 1(a), before item “N,N-dimethylamphetamine”—

Add

“2,5-Dimethoxy-N-(2-methoxybenzyl)phenethylamine”.

- (6) First Schedule, Part I, paragraph 1(a), after item “N,N-dimethylamphetamine”—

Add

“3-(1,1-Dimethylbutyl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran

4-[4-(1,1-Dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethyl-bicyclo[3.1.1]hept-2-ene-2-methanol”.

- (7) First Schedule, Part I, paragraph 1(a), after item “3-Dimethylheptyl-11-hydroxyhexahydrocannabinol”—

Add

“4-Fluoro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine”.

- (8) First Schedule, Part I, paragraph 1(a)—

Repeal

“9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol

[9-Hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate”

Substitute

“3-Hydroxy-2-[6-isopropenyl-3-methyl-cyclohex-2-en-1-yl]-5-pentyl-1,4-benzoquinone

[9-Hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate

9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol”.

- (9) First Schedule, Part I, paragraph 1(a), before item “N-[α -Methyl-3,4-(methylenedioxy)phenethyl] hydroxylamine”—

Add

“4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine

N-(2-Methoxybenzyl)-1-[3-bromo-2,5-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine”.

- (10) First Schedule, Part I, paragraph 1(a), after item “4-Methylaminorex”—

Add

“4-Methyl-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine”.

- (11) First Schedule, Part I, paragraph 1(g)—

- (a) **Repeal**

“3-(1-naphthoyl)indole or”

Substitute

“3-(1-naphthoyl)indole, 3-(2-naphthoyl)indole,”;

- (b) After “1H-indol-3-yl-(1-naphthyl)methane”—

Add

“or 1H-indol-3-yl-(2-naphthyl)methane”;

- (c) After “cycloalkylethyl”—

Add

Section 3

“, cyanoalkyl, hydroxyalkyl, haloalkyl,
(N-methylpiperidin-2-yl)methyl”.

(12) First Schedule, Part I, paragraph 1(h)—

(a) After “3-(1-naphthoyl)pyrrole”—

Add

“or 3-(2-naphthoyl)pyrrole”;

(b) After “cycloalkylethyl”—

Add

“, cyanoalkyl, hydroxyalkyl, haloalkyl,
(N-methylpiperidin-2-yl)methyl”.

(13) First Schedule, Part I, paragraph 1(i)—

(a) **Repeal**

“1-(1-naphthylmethyl)indene”

Substitute

“1-(1-naphthylmethylene)indene or 1-(2-naphthylmethylene)indene”;

(b) After “cycloalkylethyl”—

Add

“, cyanoalkyl, hydroxyalkyl, haloalkyl,
(N-methylpiperidin-2-yl)methyl”.

(14) First Schedule, Part I, paragraph 1(j), after
“cycloalkylethyl”—

Add

“, cyanoalkyl, hydroxyalkyl, haloalkyl, (N-methylpiperidin-2-yl)methyl”.

(15) First Schedule, Part I, paragraph 1(m)(v)—

Repeal the full stop

Substitute a semicolon.

(16) First Schedule, Part I, after paragraph 1(m)—

Add

- “(n) any compound (not being a compound for the time being specified in subparagraph (a)) structurally derived from 3-benzoylindole by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, cyanoalkyl, hydroxyalkyl, haloalkyl, (N-methylpiperidin-2-yl) methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;
- (o) any compound (not being a compound for the time being specified in subparagraph (a)) structurally derived from 3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, cyanoalkyl, hydroxyalkyl, haloalkyl, (N-methylpiperidin-2-yl) methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent;
- (p) any compound (not being a compound for the time being specified in subparagraph (a)) structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, cyanoalkyl, hydroxyalkyl, haloalkyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent.”.

Dangerous Drugs Ordinance (Amendment of First Schedule) Order 2015

L.N. 144 of 2015

B2281

C. Y. LEUNG
Chief Executive

26 June 2015

Explanatory Note

This Order amends Part I of the First Schedule to the Dangerous Drugs Ordinance (Cap. 134) in order to impose control on the following substances which are capable of being abused—

- (a) certain types of synthetic substances that are commonly known as NBOMe compounds;
- (b) certain other types of synthetic substances that are commonly known as synthetic cannabinoids.